Speakers: Axel Merseburger & Elizabeth Plimack
Axel Merseburger and Elizabeth Plimack highlight interesting trials in the neoadjuvant space, such as the phase 2 trial of nivolumab plus gemcitabine and cisplatin in selected patients with bladder cancer. They talk about their preferred treatment approach for cisplatin-ineligible patients in the metastatic setting, commenting also on the data of enfortumab vedotin and pembrolizumab as first-line treatment for this patient population.
This video is supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany.